Exogene focuses on the discovery of novel tumour targets shared across patients and safe and effective target-specific TCRs.
Their artificial intelligence platform rapidly screens billions of TCRs from patients in order to computationally identify rare TCRs that can target and destroy cancer cells. The AI learns from the billions of interactions between TCR and cancer cells that Exogene analyses at their labs using a range of cutting edge screening techniques.
Federico Paoletti - CEO and Co-Founder
A computational biologist with deep expertise in mathematical modelling and molecular biophysics.
Andrea Mambrini - CTO and Co-Founder
An experienced Machine Learning Scientist.
We are truly excited by the opportunity to work at the BioEscalator alongside some of the most exciting and promising biotechnology companies in the world. We believe that joining the stimulating environment at the BioEscalator will help Exogene achieve its goals to discover highly effective cell therapies for solid tumours using machine learning.
Dr Federico Paoletti - CEO and Co-Founder